Trial Profile
Multi-center study for efficacy of TAZ/PIPC on catheter-associated urinary tract infection (CAUTI)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 May 2019
Price :
$35
*
At a glance
- Drugs Piperacillin/tazobactam (Primary)
- Indications Catheter infections; Urinary tract infections
- Focus Therapeutic Use
- 03 May 2019 Status changed to discontinued.
- 13 Apr 2018 New trial record